- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 19 Nov 21 Regulation FD Disclosure
- 28 Sep 21 Entry into a Material Definitive Agreement
- 13 Aug 21 POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update
- 1 Jul 21 Unaudited pro forma condensed combined financial statements
- 30 Jun 21 Submission of Matters to a Vote of Security Holders
- 21 Jun 21 Other Events
- 9 Jun 21 Other Events
Exhibit 16.1
June 30, 2021
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read POINT Biopharma Global Inc.’s (formally known as Therapeutics Acquisition Corp.) statements included under Item 4.01 of its Form 8-K dated June 30, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on June 30, 2021, following completion of the Company’s quarterly review for the period ended March 31, 2021, which consists only of the accounts of the pre-Business Combination Special Purpose Acquisition Company. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York